Cardinal Capital Management Cut Its Johnson & Johnson (JNJ) Stake; Aware (AWRE) Sentiment Is 1.27

Aware, Inc. provides software and services for the biometrics industry worldwide. The company has market cap of $89.69 million. The companyÂ’s software products are used in government and commercial biometrics systems to identify or authenticate people. It has a 70.34 P/E ratio. It offers biometrics software products, including biometric services platform, search and match products, software development kits, and application products for fingerprint, facial, and iris modalities that enable various functions in biometrics systems, such as enrollment, analysis, and processing of biometrics images and data on workstations or mobile devices; integration of peripheral biometric capture devices; centralized workflow, transaction processing, and subsystem integration; matching of biometric samples against biometric databases to authenticate or verify identities; and analysis and processing of text identity data.

Cardinal Capital Management Inc decreased Johnson & Johnson (JNJ) stake by 2.81% reported in 2017Q3 SEC filing. Cardinal Capital Management Inc sold 3,410 shares as Johnson & Johnson (JNJ)’s stock rose 6.85%. The Cardinal Capital Management Inc holds 117,821 shares with $15.32 million value, down from 121,231 last quarter. Johnson & Johnson now has $341.48B valuation. The stock decreased 2.00% or $2.6 during the last trading session, reaching $127.28. About 9.42 million shares traded or 21.72% up from the average. Johnson & Johnson (NYSE:JNJ) has risen 12.54% since March 2, 2017 and is uptrending. It has underperformed by 4.16% the S&P500.

Investors sentiment is 0.83 in Q3 2017. Its the same as in 2017Q2. It is flat, as 45 investors sold JNJ shares while 871 reduced holdings. only 111 funds opened positions while 645 raised stakes. 1.71 billion shares or 0.90% less from 1.73 billion shares in 2017Q2 were reported. Balyasny Asset Limited Liability Company stated it has 0.22% of its portfolio in Johnson & Johnson (NYSE:JNJ). City Communication stated it has 30,659 shares or 1.33% of all its holdings. Mitsubishi Ufj Secs accumulated 0.54% or 870 shares. Iberiabank Corp reported 1.52% stake. Eagle Asset Mgmt invested 0.65% in Johnson & Johnson (NYSE:JNJ). Bowen Hanes & Incorporated holds 311,571 shares or 1.91% of its portfolio. Royal Retail Bank Of Scotland Gru Public Ltd Co has 0.68% invested in Johnson & Johnson (NYSE:JNJ) for 21,137 shares. Croft holds 2.51% of its portfolio in Johnson & Johnson (NYSE:JNJ) for 81,444 shares. Broderick Brian C holds 3.65% or 77,821 shares in its portfolio. First Comml Bank Sioux Falls has invested 3.35% of its portfolio in Johnson & Johnson (NYSE:JNJ). Jolley Asset Limited Liability holds 0.07% or 773 shares in its portfolio. Visionary Asset Management has invested 0.89% in Johnson & Johnson (NYSE:JNJ). Stratford Consulting Ltd Llc invested in 0.13% or 2,704 shares. Moreover, National Pension Serv has 1.43% invested in Johnson & Johnson (NYSE:JNJ). Smithbridge Asset Management De has 41,195 shares for 3.77% of their portfolio.

Cardinal Capital Management Inc increased Medtronic Plc stake by 7,350 shares to 74,200 valued at $5.77 million in 2017Q3. It also upped Omnicom Group Inc. (NYSE:OMC) stake by 41,665 shares and now owns 53,465 shares. Canadian Natural Resources Ltd. (NYSE:CNQ) was raised too.

Among 23 analysts covering Johnson & Johnson (NYSE:JNJ), 11 have Buy rating, 5 Sell and 7 Hold. Therefore 48% are positive. Johnson & Johnson has $170.0 highest and $90 lowest target. $137.35’s average target is 7.91% above currents $127.28 stock price. Johnson & Johnson had 91 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was maintained by Stifel Nicolaus on Tuesday, July 18 with “Hold”. The stock has “Buy” rating by Citigroup on Monday, October 23. The rating was maintained by Citigroup on Tuesday, February 27 with “Neutral”. The stock of Johnson & Johnson (NYSE:JNJ) earned “Market Perform” rating by Wells Fargo on Thursday, January 26. The stock has “Hold” rating by Piper Jaffray on Tuesday, July 18. BMO Capital Markets maintained Johnson & Johnson (NYSE:JNJ) rating on Thursday, August 31. BMO Capital Markets has “Buy” rating and $145.0 target. The firm has “Neutral” rating given on Tuesday, January 2 by JP Morgan. The rating was downgraded by Goldman Sachs to “Sell” on Wednesday, September 20. The stock has “Overweight” rating by Barclays Capital on Wednesday, April 20. On Thursday, July 14 the stock rating was maintained by Jefferies with “Hold”.

Analysts await Johnson & Johnson (NYSE:JNJ) to report earnings on April, 17. They expect $2.01 earnings per share, up 9.84% or $0.18 from last year’s $1.83 per share. JNJ’s profit will be $5.39B for 15.83 P/E if the $2.01 EPS becomes a reality. After $1.74 actual earnings per share reported by Johnson & Johnson for the previous quarter, Wall Street now forecasts 15.52% EPS growth.

Since February 15, 2018, it had 0 insider purchases, and 1 sale for $20.17 million activity. The insider Stoffels Paulus sold 155,342 shares worth $20.17M.

It closed at $4.15 lastly. It is up 14.09% since March 2, 2017 and is uptrending. It has underperformed by 2.61% the S&P500.